乳癌诊断市场规模、份额和成长分析（按类型、产品、癌症类型、应用、最终用户和地区划分）—产业预测，2026-2033年

预计到 2024 年，乳癌诊断市场规模将达到 60.4 亿美元，到 2025 年将达到 65.1 亿美元，到 2033 年将达到 118.7 亿美元，在预测期（2026-2033 年）内，复合年增长率为 7.8%。

由于早期乳癌往往缺乏症状，因此迫切需要创新解决方案，这推动了乳癌诊断市场快速发展。各公司正越来越多地利用人工智慧 (AI) 技术来提高检测和诊断的准确性，例如，一些新型 AI 驱动系统正在寻求监管部门的核准。将 AI 整合到各种成像模式中，为医院和支付方提供了更经济的选择。私人诊断中心的兴起主要是由于对影像服务的需求不断增长以及公立医院面临的种种限制。此外，发展中地区越来越多地采用翻新诊断设备，将其作为经济有效的策略。行业领导者正在推动翻新系统的广泛应用，以提高高品质诊断服务的可及性，并确保更好的患者照护。

乳癌诊断市场驱动因素

乳癌诊断市场主要受持续的技术创新所驱动，包括尖端影像技术、分子诊断方法和生物标记检测。这些创新显着提高了乳癌检测和诊断的准确性和效率。随着这些先进诊断工具的普及和有效性不断提高，其应用也日益广泛，推动了市场显着成长。这些技术的不断发展不仅改善了患者的治疗效果，也提高了医疗保健产业对可靠诊断解决方案的认知和需求，进一步促进了市场扩张。

乳癌诊断市场面临的限制因素

与乳癌相关的文化观念和社会污名可能会阻碍女性接受必要的筛检和诊断程序。这种犹豫会对疾病的早期发现率和及时诊断产生重大影响。许多女性可能因为羞耻感或害怕社会污名而放弃利用现有的医疗保健服务。这会阻碍提高公众意识、推广定期筛检的努力，最终降低乳癌诊断的整体有效性，并延迟能够改善患者预后的重要干预措施。

乳癌诊断市场趋势

乳癌诊断市场正加速向液态生物检体转型。液体活检无创技术，可分析血液样本中的循环性肿瘤细胞和游离DNA。这项创新技术因其早期检测的潜力以及有效监测治疗反应的能力而迅速受到关注，并成为传统组织切片检查的重要替代方案。液态生物检体正在改变乳癌诊断的格局，随着医疗服务提供者和患者寻求创伤更小、效率更高的诊断方案，液体活检也刺激了相关研究和投资。这一趋势预示着癌症治疗正朝着个人化医疗和改进的患者管理策略迈出重要一步。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究
• 技术进步

全球乳癌诊断市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 影像诊断
  • 乳房X光检查
  • MRI
  • 超音波
  • PET/CT
• 切片检查
• 基因组检测
• 血液检查
• 其他的

全球乳癌诊断市场规模（按产品和复合年增长率划分）（2026-2033 年）

• 基于平台的产品
  • 次世代定序
  • 微阵列
  • PCR
  • 其他的
• 设备类产品
  • 影像
  • 切片检查

全球乳癌诊断市场规模（按癌症类型和复合年增长率划分）（2026-2033 年）

• 乳管原位癌
• 浸润性乳管癌
• 发炎性乳癌
• 转移性乳癌

全球乳癌诊断市场规模（按应用及复合年增长率划分）（2026-2033 年）

• 筛检
• 诊断和预后
• 预后诊断
• 研究
• 其他的

全球乳癌诊断市场规模（按最终用户和复合年增长率划分）（2026-2033 年）

• 医院和诊所
• 诊断中心
• 医疗检查室
• 其他的

全球乳癌诊断市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Hologic（USA）
• Natera（USA）
• Siemens Healthineers（Germany）
• Leica Biosystems（Germany）（Parent company：Danaher Corporation）
• Roche Diagnostics（Switzerland）
• GE Healthcare（USA）
• Philips Healthcare（Netherlands）
• Abbott Laboratories（USA）
• Thermo Fisher Scientific（USA）
• Becton, Dickinson and Company（USA）
• Agilent Technologies（USA）
• Illumina（USA）
• PerkinElmer（USA）
• Qiagen（Germany）
• Bio-Rad Laboratories（USA）
• Cepheid（USA）（Parent company：Danaher Corporation）
• Myriad Genetics（USA）
• Fujifilm Holdings Corporation（Japan）
• Canon Medical Systems Corporation（Japan）
• Hitachi Medical Systems（Japan）

结论与建议

Breast Cancer Diagnostics Market size was valued at USD 6.04 Billion in 2024 and is poised to grow from USD 6.51 Billion in 2025 to USD 11.87 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The breast cancer diagnostics market is evolving rapidly, driven by the pressing need for innovative solutions due to the often asymptomatic nature of early-stage breast cancer. Companies are increasingly leveraging artificial intelligence (AI) technologies to improve detection and diagnostic accuracy, with a notable example being a new AI-driven system aiming for regulatory approval. The integration of AI across diverse imaging modalities presents hospitals and payers with more economical options. The rise of private diagnostic centers is largely influenced by the growing demand for imaging services and the constraints faced by public hospitals. Additionally, in developing regions, the adoption of refurbished diagnostic equipment is gaining traction as a cost-effective strategy. Industry leaders are promoting refurbished systems to facilitate access to quality diagnostics, ensuring better patient care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Breast Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Breast Cancer Diagnostics Market Segments Analysis

Global Breast Cancer Diagnostics Market is segmented by Type, Product, Cancer Type, Application, End-user and region. Based on Type, the market is segmented into Imaging, Biopsy, Genomic Tests, Blood Tests and Others. Based on Product, the market is segmented into Platform-based Products and Instrument-based Products. Based on Cancer Type, the market is segmented into Ductal carcinoma in situ, Invasive ductal carcinoma, Inflammatory breast cancer and Metastatic breast cancer. Based on Application, the market is segmented into Screening, Diagnostic and Predictive, Prognostic, Research and Others. Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Medical Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Breast Cancer Diagnostics Market

The Breast Cancer Diagnostics market is being significantly propelled by ongoing technological advancements, including cutting-edge imaging techniques, molecular diagnostic methods, and biomarker assays. These innovations greatly enhance the accuracy and efficiency of breast cancer detection and diagnosis. As these sophisticated diagnostic tools become more accessible and effective, their adoption is increasing, leading to substantial growth in the market. The continuous evolution of these technologies not only improves patient outcomes but also fosters greater awareness and demand for reliable diagnostic solutions within the healthcare sector, further stimulating the market's expansion.

Restraints in the Breast Cancer Diagnostics Market

Cultural beliefs and prevalent social stigma related to breast cancer can deter women from pursuing necessary screening and diagnostic procedures. This reluctance can significantly affect the rates of early detection and timely diagnosis of the disease. Many women may feel ashamed or fearful of societal judgment, leading to a lack of engagement with available healthcare services. Consequently, such attitudes can hinder public awareness initiatives aimed at promoting regular check-ups and screenings, ultimately compromising the overall effectiveness of breast cancer diagnostics and delaying vital interventions that could improve outcomes for those affected by the disease.

Market Trends of the Breast Cancer Diagnostics Market

The breast cancer diagnostics market is increasingly leaning towards liquid biopsies, a non-invasive method that analyzes circulating tumor cells and cell-free DNA from blood samples. This innovative approach is rapidly gaining traction due to its potential for early detection and the ability to monitor treatment responses effectively, positioning it as a crucial alternative to traditional tissue biopsies. As healthcare providers and patients seek less invasive, more efficient diagnostic options, liquid biopsies are reshaping the landscape of breast cancer diagnostics, driving research and investment. This trend signals a significant shift towards personalized medicine and improved patient management strategies in oncology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Breast Cancer Diagnostics Market Size by Type & CAGR (2026-2033)

• Market Overview
• Imaging
  • Mammography
  • MRI
  • Ultrasound
  • PET/CT
• Biopsy
• Genomic Tests
• Blood Tests
• Others

Global Breast Cancer Diagnostics Market Size by Product & CAGR (2026-2033)

• Market Overview
• Platform-based Products
  • Next-generation Sequencing
  • Microarrays
  • PCR
  • Others
• Instrument-based Products
  • Imaging
  • Biopsy

Global Breast Cancer Diagnostics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Ductal carcinoma in situ
• Invasive ductal carcinoma
• Inflammatory breast cancer
• Metastatic breast cancer

Global Breast Cancer Diagnostics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Screening
• Diagnostic and Predictive
• Prognostic
• Research
• Others

Global Breast Cancer Diagnostics Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers
• Medical Laboratories
• Others

Global Breast Cancer Diagnostics Market Size & CAGR (2026-2033)

• North America (Type, Product, Cancer Type, Application, End-user)
  • US
  • Canada
• Europe (Type, Product, Cancer Type, Application, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product, Cancer Type, Application, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product, Cancer Type, Application, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product, Cancer Type, Application, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Hologic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Germany) (Parent company: Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cepheid (USA) (Parent company: Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Medical Systems Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hitachi Medical Systems (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations